- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01491477
INFUSE ® Bone Graft/CORNERSTONE-SR® Allograft Ring/ATLANTIS® Anterior Cervical Plate System Pivotal Trial
Study of Recombinant Human Bone Morphogenetic Protein-2 and Absorbable Collagen Sponge With the Cornerstone-SR™ Allograft Ring and the ATLANTIS™ Anterior Cervical Plate System in Treatment of Patients With Degenerative Cervical Disc Disease
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Cervical disc disease defined as: intractable radiculopathy and/or myelopathy with at least one of the following items producing symptomatic nerve root and/or spinal cord compression which is documented by diagnostic imaging procedures:
- herniated disc;
- osteophyte formation;
- decreased disc height;
- thickening of ligamentous tissue;
- disc degeneration; and/or
- facet joint degeneration.
- Has preoperative Neck Disability Index score > 30;
- Has single cervical disc disease level requiring fusion from C2 to C7;
- No previous surgical intervention at the involved fusion level;
- Unresponsive to nonoperative treatment for approximately six weeks or has the presence of progressive symptoms or signs of nerve root or spinal cord compression in face of continued nonoperative management;
- Is at least 18 years of age, inclusive at time of surgery;
- If of child-bearing potential, patient is non-pregnant, non-nursing, and agrees to use adequate contraception for 1 year following surgery;
- Is willing and able to comply with study plan and sign the consent form.
Exclusion Criteria:
- Has cervical spinal condition requiring surgical treatment other than symptomatic cervical disc disease at the involved level.
- Has a condition which requires postoperative medications that interfere with fusion, such as steroids or prolonged non-steroidal anti-inflammatory drugs excluding routine perioperative anti-inflammatory drugs. This does not include low dose aspirin for prophylactic anticoagulation.
- Has been previously diagnosed with osteopenia, or osteomalacia.
Has any of the following that may be associated with a diagnosis of osteoporosis (if "Yes" to any of the below risk factors, a DEXA Scan will be required to determine eligibility).
- Postmenopausal Non-Black female over 60 years of age and weighs less than 140 pounds.
- Postmenopausal female that has sustained a non-traumatic hip, spine, or wrist fracture.
- Male over the age of 70.
- Male over the age of 60 that has sustained a non-traumatic hip or spine fracture.
If the level of BMD is a T score of -3.5 or a T score of -2.5 with vertebral crush fracture, the patient is excluded from the study.
- Has presence of active malignancy or prior history of malignancy, except for basal cell carcinoma of the skin.
- Has overt or active bacterial infection, either local or systemic.
- Has a documented titanium alloy allergy or intolerance.
- Is mentally incompetent. If questionable, obtain psychiatric consult.
- Is a prisoner.
- Is an alcohol and/or drug abuser as defined by currently undergoing treatment for alcohol and/or drug usage.
- Has received drugs which may interfere with bone metabolism within two weeks prior to the planned date of spinal fusion surgery (e.g., steroids or methotrexate), excluding routine perioperative anti-inflammatory drugs.
- Has a history of autoimmune disease (Systemic Lupus Erythematosus or Dermatomyositis).
- Has a history of exposure to injectable collagen implants.
- Has a history of hypersensitivity to protein pharmaceuticals (monoclonal antibodies or gamma globulins) or collagen.
- Has received treatment with an investigational therapy within 28 days prior to implantation surgery or such treatment is planned during the 16 weeks following rhBMP-2/ACS implantation.
- Has received any previous exposure to any/all BMP's of either human or animal extraction.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: INFUSE™ Bone Graft
|
Cornerstone-SR™ allograft bone containing recombinant human Bone Morphogenetic Protein (rhBMP-2) soaked into an absorbable collagen sponge (ACS) used in conjunction with ATLANTIS™ anterior cervical plate system.
Other Names:
|
Active Comparator: Autogenous bone
|
Cornerstone-SR™ allograft bone packed with autogenous iliac crest bone graft used in conjunction with ATLANTIS™ anterior cervical plate system.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Success
Time Frame: 12 month
|
A patient will be considered an overall success if all of the following conditions are met:
|
12 month
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Disc Height Measurement
Time Frame: 12 month
|
12 month
|
General Health Status (SF-36)
Time Frame: 12 month
|
12 month
|
Pain Status (neck pain, arm pain)
Time Frame: 12 month
|
12 month
|
Patient Satisfaction
Time Frame: 12 month
|
12 month
|
Patient Global Perceived Effect
Time Frame: 12 month
|
12 month
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P01-04
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Degenerative Cervical Disc Disease
-
Medtronic Spinal and BiologicsCompletedDegenerative Cervical Disc DiseaseSaudi Arabia, Greece, Serbia, Hungary, Czech Republic, Kuwait, Poland, Slovakia
-
Assiut UniversityNot yet recruiting
-
DePuy InternationalTerminatedCervical Degenerative Disc DiseaseAustralia, Germany, Italy, Malaysia, Netherlands, Spain, United Kingdom
-
Assistance Publique - Hôpitaux de ParisTerminatedCervical Degenerative Disc Disease | Kyphosis | Lumbar Degenerative Disc DiseaseFrance
-
Synergy Spine SolutionsMCRARecruitingCervical Degenerative Disc DiseaseUnited States
-
Orthofix Inc.TerminatedCervical Degenerative Disc DiseaseUnited States
-
Synergy Spine SolutionsMCRANot yet recruitingCervical Degenerative Disc DiseaseUnited Kingdom
-
Medtronic Spinal and BiologicsCompletedCervical Degenerative Disc DiseaseUnited States
-
NuVasiveCompletedCervical Degenerative Disc DiseaseUnited States
-
Alphatec Spine, Inc.Terminated
Clinical Trials on INFUSE™ Bone Graft/CORNERSTONE-SR™ /ATLANTIS™
-
Medtronic Spinal and BiologicsCompletedDegenerative Cervical Disc Disease
-
Medtronic Spinal and BiologicsRecruitingIntervertebral Disc Degeneration | Spinal Fusion | Lumbar Disc DiseaseKorea, Republic of
-
Medtronic Spinal and BiologicsRecruitingDegenerative Disease of the Lumbosacral SpineUnited States, China
-
Medtronic Spinal and BiologicsCompletedDegenerative Disc Disease
-
Medtronic Spinal and BiologicsCompleted
-
Zetagen Therapeutics, IncRecruitingMetastatic Breast Cancer in the SpineCanada
-
Medtronic Spinal and BiologicsCompleted
-
Lombard MedicalSuspendedAbdominal Aortic AneurysmsUnited Kingdom, Germany, New Zealand, Spain, Czechia, Italy
-
Hospital for Special Surgery, New YorkAvailableArthroplasty of the PIP JointUnited States
-
Hospital for Special Surgery, New YorkApproved for marketingArthroplasty of the MCP JointUnited States